Kanilad

Lacosamide, the active ingredient in Kanilad, is an anticonvulsant presented as an oral dosage form for oral use. It is employed as adjunctive therapy for partial‑onset (focal) seizures in patients with epilepsy. GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on focal seizure activity in epilepsy.

Partial‑onset (focal) seizures: Reduces seizure frequency when added to existing antiepileptic regimens. Focal epilepsy: Improves overall seizure control as part of combination therapy. Adjunctive epilepsy therapy: Provides additional seizure reduction for patients not fully controlled by other agents.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Elevated liver enzymes - Anaphylactic reactions

When prescribing lacosamide, clinicians should consider several safety aspects.

Renal impairment: Adjust dose or monitor renal function. Hepatic impairment: Monitor liver enzymes and consider dose modification. Cardiac conduction: Avoid in patients with known PR‑interval prolongation. Pregnancy: Use only if potential benefit justifies potential risk; data are limited. Drug interactions: Review concomitant medications for possible interactions. Store at room temperature: Keep in original packaging, protect from moisture and heat.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin) may markedly reduce lacosamide exposure. - Co‑administration with drugs that prolong PR interval (e.g., quinidine, amiodarone) can increase cardiac risk.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate) may increase adverse‑effect burden. - Oral contraceptives: Lacosamide may reduce contraceptive efficacy. - Alcohol: May enhance central nervous system depression.